Literature DB >> 21526357

Prevalence of neuropathic pain among Black African patients suffering from common low back pain.

Dieu-Donné Ouédraogo1, Victor Nonguierma, Christian Napon, Abel Kabré, Hervé Tiéno, Oumar Guira, Jean Kaboré, Joseph Y Drabo.   

Abstract

To study the prevalence and semiotic characteristics of neuropathic pain in the common low back pain to the Black African subject. This was a prospective cross-sectional survey carried on from April 1 2009 to August 31 2009 in consultations of rheumatology, neurology, and neurosurgery at the University Hospital Yalgado Ouédraogo in Ouagadougou (Burkina Faso). All patients with a low back pain or a common lomboradiculalgie were included. DN4 questionnaire was used for the diagnosis of neuropathic pain. One hundred and seven patients have been recruited during the study period; Sixty-four (59.80%) were female (sex ratio M/F: 0.67). The average age was 34.11 ± 13.46 years of age with extremes of 20 and 79. The average duration of disease was 48.53 months with extremes of 10 days and 50 years. Eighty-seven patients (81.31%) had a disease duration, which was 3 months longer. Sixty-six patients (61.70%) had a predominant lomboradiculalgie; among the remaining 41, low back pain predominated. Average intensity of pain was 62.81 ± 22.43 (on a scale of 100). A sign of Lasèque was present in the 41 (38.30%) patients. Fifty-three (49.5%) patients had a neuropathic pain. The prevalence of neuropathy signs according to the DN4 questionnaire was as follows: burning (n = 37; 34.58%), painful cold (n = 13; 12.15%), electric shocks (n = 31; 38.97%), pins and needles (n = 34; 31.77%), tingling (n = 35; 32.71%), numbness (n = 45; 42.05%), itching (n = 18; 16.82%), touch hypoesthesia (n = 35; 32.71%), pinprick (n = 33; 30.84%), and tactile allodynia (n = 21; 19.62%). Among the studied variables, the presence of a radiculalgy was statistically associated with neuropathic pain. The lomboradiculalgie of the Black African subject associates neuropathic pain observed in half of patients. Treatment must therefore always take account of this association. However, further studies are needed before any definitive conclusion.

Entities:  

Mesh:

Year:  2011        PMID: 21526357     DOI: 10.1007/s00296-011-1945-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  13 in total

1.  The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs.

Authors:  M Bennett
Journal:  Pain       Date:  2001-05       Impact factor: 6.961

2.  Prevalence of chronic pain with neuropathic characteristics in the general population.

Authors:  Didier Bouhassira; Michel Lantéri-Minet; Nadine Attal; Bernard Laurent; Chantal Touboul
Journal:  Pain       Date:  2007-09-20       Impact factor: 6.961

3.  Identifying neuropathic pain among patients with chronic low-back pain: use of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale.

Authors:  Abdullah M Kaki; Ahmed Zaki El-Yaski; Ehab Youseif
Journal:  Reg Anesth Pain Med       Date:  2005 Sep-Oct       Impact factor: 6.288

4.  Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4).

Authors:  Didier Bouhassira; Nadine Attal; Haiel Alchaar; François Boureau; Bruno Brochet; Jean Bruxelle; Gérard Cunin; Jacques Fermanian; Patrick Ginies; Aurélie Grun-Overdyking; Hélène Jafari-Schluep; Michel Lantéri-Minet; Bernard Laurent; Gérard Mick; Alain Serrie; Dominique Valade; Eric Vicaut
Journal:  Pain       Date:  2005-01-26       Impact factor: 6.961

5.  EFNS guidelines on pharmacological treatment of neuropathic pain.

Authors:  N Attal; G Cruccu; M Haanpää; P Hansson; T S Jensen; T Nurmikko; C Sampaio; S Sindrup; P Wiffen
Journal:  Eur J Neurol       Date:  2006-11       Impact factor: 6.089

6.  The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey.

Authors:  Nicola Torrance; Blair H Smith; Michael I Bennett; Amanda J Lee
Journal:  J Pain       Date:  2006-04       Impact factor: 5.820

Review 7.  The evaluation of neuropathic components in low back pain.

Authors:  Rainer Freynhagen; Ralf Baron
Journal:  Curr Pain Headache Rep       Date:  2009-06

8.  Development of a neuropathic pain questionnaire.

Authors:  Steven J Krause; Misha-Miroslav Backonja
Journal:  Clin J Pain       Date:  2003 Sep-Oct       Impact factor: 3.442

Review 9.  [Rheumatic diseases in black Africa].

Authors:  M Mijiyawa
Journal:  Rev Rhum Ed Fr       Date:  1993-06

10.  Development and validation of the Neuropathic Pain Symptom Inventory.

Authors:  Didier Bouhassira; Nadine Attal; Jacques Fermanian; Haiel Alchaar; Michèle Gautron; Etienne Masquelier; Sylvie Rostaing; Michel Lanteri-Minet; Elisabeth Collin; Jacques Grisart; François Boureau
Journal:  Pain       Date:  2004-04       Impact factor: 6.961

View more
  8 in total

1.  Prevalence and associations of neuropathic pain in a cohort of multi-ethnic Asian low back pain patients.

Authors:  Yueting Kew; Cheng-Yin Tan; Chong-Jing Ng; Sue-Sien Thang; Leong-Hooi Tan; Yvonne Khaii Khoo; Jun-Ni Lim; Jia-Hui Ng; Chris Yin-Wei Chan; Mun-Keong Kwan; Khean-Jin Goh
Journal:  Rheumatol Int       Date:  2016-12-24       Impact factor: 2.631

2.  Neuropathic pain in pregnant Turkish women with lumbopelvic pain and its impact on health-related quality of life.

Authors:  Filiz Eser; Saniye Nebioğlu; Aygün Aliyeva; Ayşegül Kılıçarslan; Cemal Reşat Atalay; Gizem Özcanlı; Şükran Erten; Funda Uysal
Journal:  Eur J Rheumatol       Date:  2017-06-20

3.  Proportion of neuropathic pain in the back region in chronic low back pain patients -a multicenter investigation.

Authors:  Jun Li; Jing He; Hu Li; Bi-Fa Fan; Bo-Tao Liu; Peng Mao; Yi Jin; Zhu-Qiang Cheng; Ting-Jie Zhang; Zhi-Fang Zhong; Si-Ji Li; Sai-Nan Zhu; Yi Feng
Journal:  Sci Rep       Date:  2018-11-08       Impact factor: 4.379

4.  Pharmacological target therapy of neuropathic pain and patient-reported outcomes in patients with chronic low back pain in Korea: Results from the NLBP Outcomes Research.

Authors:  Jae Taek Hong; Jin-Hwan Kim; Keun-Su Kim; Chong-Suh Lee; Hyun-Chul Shin; Woo-Kyung Kim; Joo-Han Kim; Jung-Kil Lee; In-Soo Kim; Yoon Ha; Soo-Bin Im; Sang Woo Kim; In-Ho Han; Jun-Jae Shin; ByeongCheol Rim; Kyung-Soo Suk; Jin-Hyok Kim; Ye-Soo Park; Bong-Soon Chang; Deuk Soo Jun; Young-Hoon Kim; Jung-Hee Lee; Woo-Kie Min; Jung Sub Lee; Si-Young Park; In-Soo Oh; Jae-Young Hong; Bo-Jeong Seo; Young-Joo Kim; Juneyoung Lee
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

5.  Diagnostic utility of patient history, clinical examination and screening tool data to identify neuropathic pain in low back-related leg pain: protocol for a systematic review.

Authors:  Jai Mistry; Nicola R Heneghan; Timothy Noblet; Deborah Falla; Alison Rushton
Journal:  BMJ Open       Date:  2019-11-24       Impact factor: 2.692

6.  Clinical indicators to identify neuropathic pain in low back-related leg pain: protocol for a modified Delphi study.

Authors:  Jai Mistry; Deborah Falla; Tim Noblet; Nicola R Heneghan; Alison B Rushton
Journal:  BMJ Open       Date:  2020-02-17       Impact factor: 2.692

Review 7.  Neuropathic pain in Mali: The current situation, comprehensive hypothesis, which therapeutic strategy for Africa?

Authors:  Youssoufa Maiga; Oumar Sangho; Fatoumata Konipo; Seybou Diallo; Souleymane Dit Papa Coulibaly; Modibo Sangare; Yann Péréon; Bernard Giumelli; Martin Sanou; Awa Coulibaly; Salimata Diallo; Mariam Daou; Zoumana Traoré; Mohamed Albakaye; Hamar A Traoré; Cheick Oumar Guinto; Madani Ouologem; Callixte Kuate-Tegueu; Didier Bouhassira; Robert Cowan; Julien Nizard
Journal:  eNeurologicalSci       Date:  2021-01-09

8.  Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry.

Authors:  Michael A Ueberall; Carlos Vila Silván; Ute Essner; Gerhard H H Mueller-Schwefe
Journal:  Pain Med       Date:  2022-04-08       Impact factor: 3.750

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.